A Phase 1/2 interventional study of RAD001 and Imatinib 600mg/day (Glevec is the brand name for imatinib) in Gastrointestinal Stromal Tumors, sponsored by Novartis Pharmaceuticals. Completed at 16 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-25.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Gastrointestinal Stromal Tumors by Novartis — none open to participants now, none under way, none of them phase 3. Gastrointestinal Stromal Tumors · Novartis.
Among the 27 studies in Gastrointestinal Stromal Tumors by Novartis, this one is the 10th largest by enrollment of the 26 interventional ones that give a count, is one of 3 that started in 2002, is the only one in phase 1/2, and was the 17th registered.
343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.
Browse Gastrointestinal Stromal Tumors studies →None of the 27 studies in Gastrointestinal Stromal Tumors by Novartis is open now. The open studies under Gastrointestinal Stromal Tumors, anywhere →
Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 14 · Phase 3 4 · Phase 4 5
First in 2000; this study’s year is marked. 3 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 117 is above the median of 50 across 252 interventional studies indexed under Gastrointestinal Stromal Tumors.
Median enrollment 76 across the 26 interventional studies. Of the 26 that completed or were terminated, 14 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 27 studies in Gastrointestinal Stromal Tumors by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial was a Phase I/II, non-randomized, open label, multi-center study, following a sequential 2-part design.
The first part, Phase I, was designed to assess whether there is a pharmacokinetic interaction between Glivec/Gleevec (imatinib) and RAD001(everolimus) as well as to collect safety data when these two drugs are co-administered. The second part, (Phase II), was designed to assess the potential efficacy of the combination in imatinib-resistant GIST patients in two strata of patients:
It was decided to discontinue the study and close to further enrollment based on alternative treatment options that became available. Phase 1 and Phase 2 Stratum 1 were ended early on 02-Nov-2006. Investigators were allowed to complete the enrollment in the Phase 2 Stratum 2.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Phase l:
Phase ll:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RAD001 20 mg was given once a week.
Drug: RAD001
RAD001 2.5 mg was given in combination with Glivec/Gleevec 600mg/day.
Drug: RAD001 · Drug: Imatinib 600mg/day (Glevec is the brand name for imatinib)
RAD001 5 mg was given in combination with Glivec/Gleevec 600mg/day.
Drug: RAD001 · Drug: Imatinib 600mg/day (Glevec is the brand name for imatinib)
RAD001 2.5 mg was given in combination with Glivec/Gleevec 800mg/day.
Drug: RAD001 · Drug: Imatinib 600mg/day (Glevec is the brand name for imatinib)
All first-line resistant/refractory patients received RAD001 2.5mg/day in combination with Glivec/Gleevec at a dose of 600mg/day.
Drug: RAD001 · Drug: Imatinib 800mg/day (Glevec is the brand name for imatinib)
All post-second-line patients received RAD001 2.5mg/day in combination with Glivec/Gleevec at a dose of 600mg/day
Drug: RAD001 · Drug: Imatinib 800mg/day (Glevec is the brand name for imatinib)
RAD001 was in tablets of 0.5 mg, 1.0 mg, 2.5 mg and 5.0 mg strength and was taken by mouth, once a week or once a day depending upon the treatment group the patient was enrolled into.
Also known as: everolimus
Drug page: Imatinib
Glivec/Gleevec was supplied as commercialized 100 mg and 400 mg tablets. Gleevec/Glivec was provided as capsules of 100 mg strength in bottles containing 60 capsules each. The use of this supply was study center specific. Glivec/Gleevec was taken, by mouth, at a dose of 300 mg twice a day. The Glivec/Gleevec regimen was changed from 600 mg once a day to 300 mg BID, by an amendment since taking too many tablets at once was difficult for patients with gastro-intestinal disease. In the phase II part of the study all patients received Glivec 600 mg/day.
Also known as: STI571
Drug page: Imatinib
Glivec/Gleevec was supplied as commercialized 100 mg and 400 mg tablets. Gleevec/Glivec was provided as capsules of 100 mg strength in bottles containing 60 capsules each. The use of this supply was study center specific. Glivec/Gleevec was taken, by mouth. In the phase II part of the study all patients received Glivec 600 mg/day, except for 2 patients who received Glivec at a dose of 800 mg/day. This dose was permitted in Phase II as it was found to be safe in Phase I.
Also known as: STI571
Number of Participants With Adverse Events (AEs): Phase I & II
Assessed safety and tolerability of the combination administration of RAD001 and imatinib when given to patients with imatinib-refractory gastro-intestinal stromal tumors (GIST) by number of participants with adverse events.
Time frame: 4 - 8 weeks
Best Overall Response (BOR) as Assessed by Overall Response (Complete Response (CR) & Partial Response (PR)) - Phase I & II
Assessed clinical efficacy of the combination regimen in this patient population per BOR by Overall response (CR + PR). Complete response: Disappearance of all target lesions; Partial response: ≥ 30% decrease in the sum of the longest diameter of target lesions compared to baseline (and not ≥20% increase compared to smallest sum).
Time frame: 6 - 8 weeks
Trough Concentrations for RAD001 and for Imatinib - Phase II
Assessed the pharmacokinetics (PK) of the combination administration of RAD001 and imatinib in this patient population.
Time frame: Part II Daily regimen: Baseline, Days 8, 15 and thereafter approximately every two months starting at month 3 whenever possible
Overall Survival (OS) - Phase I & II
Assessed clinical efficacy of the combination regimen in this patient population per Overall Survival (OS). Overall survival was defined as the time from date of start of treatment to date of death due to any cause. For patients still receiving study medication at the time of the analysis, survival was censored at the date of last examination. If a patient was not known to have died but was no longer continuing with study medication, survival was censored at the date of last contact.
Time frame: about 60 months
4-Month Progression-free Survival (PFS) Rate - Phase II
Assessed clinical efficacy of the combination regimen in this patient population per Progression-free survival (PFS). Progression-free survival (PFS) was the time from date of start of treatment to the date of first documented progression or death due to any cause. Per protocol (PP) population includes patients with no known overall lesion response during 4 months +/- 2 weeks, or who later had response of CR/PR/stable disease (SD). PP population excludes patients with no known response during 4 months + / -2 weeks and no subsequent CR/PR/SD.
Time frame: about 4 months
Progression-free Survival (PFS) - Phase II
Assessed clinical efficacy of the combination regimen in this patient population per Progression-free survival (PFS). Progression-free survival (PFS) was the time from date of start of treatment to the date of first documented progression or death due to any cause. If a patient had not progressed or died, progression-free survival was censored at the time of last adequate tumor assessment. According to the study protocol no tumor assessments were performed after discontinuation of treatment with study drug. Therefore, for all patients who discontinued treatment without a documented progression but died thereafter, death was considered as PFS event only if it occurred within the regular safety follow-up of 28 days after discontinuation. Otherwise, the PFS time was censored at the last adequate tumor assessment.
Time frame: about 60 months
mTOR Pathway Activity Before Treatment, and Inhibition of mTOR Pathway Activity During Treatment as a Predictive Factor of Response, as Shown by Molecular Pathological Examination of the Tumor.
assess mTOR pathway activity before treatment, and inhibition of mTOR pathway activity during treatment as a predictive factor of response, as shown by molecular pathological examination of the tumor.
Time frame: about 60 months
Relationship Between Drug-induced Changes in the Principal Molecular Marker of Intratumoral mTOR Activity and Changes in Other Molecular Markers of Tumoral Activity (e.g. Indicators of Pathway Activity, Cell Proliferation and Apoptosis).
assess the relationship between drug-induced changes in the principal molecular marker of intratumoral mTOR activity and changes in other molecular markers of tumoral activity (e.g. indicators of pathway activity, cell proliferation and apoptosis).
Time frame: about 60 months
Relationship Between Drug-induced Changes in Tumoral Metabolism, as Shown by Functional Imaging With 18F-fluorodeoxyglucose Positron Emission Tomography (FDC-PET), With Clinical Outcome and Changes in Molecular Pathology.
assess the relationship between drug-induced changes in tumoral metabolism, as shown by functional imaging with 18F-fluorodeoxyglucose positron emission tomography (FDC-PET), with clinical outcome and changes in molecular pathology.
Time frame: about 60 months
This trial was a Phase I/II study, following a sequential 2-part design. The 1st part was designed to assess whether there was a pharmacokinetic interaction between Glivec/Gleevec and RAD001. The 2nd part was designed to assess the potential efficacy of the combination in Glivec/Gleevec-resistant GIST patients in 2 strata of patients.
| Milestone | Phase l: RAD001 20mg/Week | Phase l: RAD001 2.5mg/Day + Glivec 600mg/Day | Phase l: RAD001 5mg/Day + Glivec 600mg/Day | Phase l: RAD001 2.5mg/Day + Glivec 800mg/Day | Phase ll - Stratum l (First-line Resistant/Refractory): RAD001 2.5mg/Day + Glivec 600mg/Day | Phase ll: Stratum ll (Post Second-line Therapy) |
|---|---|---|---|---|---|---|
| Started | 13 | 13 | 5 | 11 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 13 | 13 | 5 | 11 | 0 | 0 |
| Withdrew: Adverse event | 1 | 4 | 2 | 3 | 0 | 0 |
| Withdrew: Abnormal laboratory value(s) | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Abnormal test procedure result(s) | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Disease progression | 12 | 8 | 2 | 5 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Death | 0 | 1 | 0 | 1 | 0 | 0 |
| Milestone | Phase l: RAD001 20mg/Week | Phase l: RAD001 2.5mg/Day + Glivec 600mg/Day | Phase l: RAD001 5mg/Day + Glivec 600mg/Day | Phase l: RAD001 2.5mg/Day + Glivec 800mg/Day | Phase ll - Stratum l (First-line Resistant/Refractory): RAD001 2.5mg/Day + Glivec 600mg/Day | Phase ll: Stratum ll (Post Second-line Therapy) |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 28 | 47 |
| Completed | 0 | 0 | 0 | 0 | 0 | 1 |
| Not completed | 0 | 0 | 0 | 0 | 28 | 46 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 2 | 10 |
| Withdrew: Abnormal laboratory values | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Disease progression | 0 | 0 | 0 | 0 | 23 | 31 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 2 | 3 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 1 | 1 |
Assessed safety and tolerability of the combination administration of RAD001 and imatinib when given to patients with imatinib-refractory gastro-intestinal stromal tumors (GIST) by number of participants with adverse events.
| Participants | Phase l: RAD001 20mg/Week | Phase l: RAD001 2.5mg/Day + Glivec 600mg/Day | Phase l: RAD001 5mg/Day + Glivec 600mg/Day | Phase l: RAD001 2.5mg/Day + Glivec 800mg/Day | Phase ll - Stratum l (First-line Resistant/Refractory): RAD001 2.5mg/Day + Glivec 600mg/Day | Phase ll: Stratum ll (Post Second-line Therapy) |
|---|---|---|---|---|---|---|
| Number of Participants With Adverse Events (AEs): Phase I & II | 13 | 13 | 5 | 11 | 27 | 47 |
Assessed clinical efficacy of the combination regimen in this patient population per BOR by Overall response (CR + PR). Complete response: Disappearance of all target lesions; Partial response: ≥ 30% decrease in the sum of the longest diameter of target lesions compared to baseline (and not ≥20% increase compared to smallest sum).
| Percentage of Participants | Phase l: RAD001 20mg/Week | Phase l: RAD001 2.5mg/Day + Glivec 600mg/Day | Phase l: RAD001 5mg/Day + Glivec 600mg/Day | Phase l: RAD001 2.5mg/Day + Glivec 800mg/Day | Phase ll - Stratum l (First-line Resistant/Refractory): RAD001 2.5mg/Day + Glivec 600mg/Day | Phase ll: Stratum ll (Post Second-line Therapy) |
|---|---|---|---|---|---|---|
| Best Overall Response (BOR) as Assessed by Overall Response (Complete Response (CR) & Partial Response (PR)) - Phase I & II | 0 (0.0 to 0.0) | 1 (0.2 to 36.0) | 0 (0.0 to 0.0) | 0.0 (0.0 to 0.0) | 0 (0.0 to 0.0) | 1 (0.1 to 11.3) |
Assessed the pharmacokinetics (PK) of the combination administration of RAD001 and imatinib in this patient population.
| ng/mL | Phase ll - Stratum l (First-line Resistant/Refractory): RAD001 2.5mg/Day + Glivec 600mg/Day | Phase ll: Stratum ll (Post Second-line Therapy) |
|---|---|---|
| Week 2: RAD001 | 24.300 (24.30 to 24.30) | 12.100 (5.80 to 17.20) |
| Week 3: RAD001 | 19.900 (19.90 to 19.90) | 12.750 (7.62 to 23.30) |
| Week 9: RAD001 | — | 10.950 (10.40 to 11.50) |
| Month 4: RAD001 | — | 7.840 (6.90 to 10.30) |
| Baseline: Imatinib | 472.00 (472.0 to 472.0) | 501.50 (402.0 to 1210.0) |
| Week 2: Imatinib | 626.50 (549.0 to 704.0) | 540.00 (330.0 to 1970.0) |
| Week 3: Imatinib | 572.00 (203.0 to 590.0) | 718.00 (412.0 to 4040.0) |
| Week 9: Imatinib | — | 899.0 (295.0 to 1780.0) |
| Month 4: Imatinib | 333.00 (333.0 to 333.0) | 446.00 (89.9 to 1350.0) |
| Month 6: Imatinib | 181.00 (181.0 to 181.0) | 2040.00 (2040.0 to 2040.0) |
| Month 8: Imatinib | — | 575.00 (566.0 to 584.0) |
| Month 12: Imatinib | — | 324.00 (324.0 to 324.0) |
Assessed clinical efficacy of the combination regimen in this patient population per Overall Survival (OS). Overall survival was defined as the time from date of start of treatment to date of death due to any cause. For patients still receiving study medication at the time of the analysis, survival was censored at the date of last examination. If a patient was not known to have died but was no longer continuing with study medication, survival was censored at the date of last contact.
| months | Phase l: RAD001 20mg/Week | Phase l: RAD001 5mg/Day + Glivec 600mg/Day | Phase l: RAD001 2.5mg/Day + Glivec 600mg/Day | Phase l: RAD001 2.5mg/Day + Glivec 800mg/Day | Phase ll - Stratum l (First-line Resistant/Refractory): RAD001 2.5mg/Day + Glivec 600mg/Day | Phase ll: Stratum ll (Post Second-line Therapy) |
|---|---|---|---|---|---|---|
| Overall Survival (OS) - Phase I & II | 9.4 (5.6 to 13.8) | 10.9 (3.3 to NA) | 18.7 (3.8 to NA) | NA (12.0 to NA) | 14.9 (14.9 to NA) | 10.7 (6.3 to 16.8) |
assess mTOR pathway activity before treatment, and inhibition of mTOR pathway activity during treatment as a predictive factor of response, as shown by molecular pathological examination of the tumor.
No measurements were reported for this outcome.
assess the relationship between drug-induced changes in the principal molecular marker of intratumoral mTOR activity and changes in other molecular markers of tumoral activity (e.g. indicators of pathway activity, cell proliferation and apoptosis).
No measurements were reported for this outcome.
assess the relationship between drug-induced changes in tumoral metabolism, as shown by functional imaging with 18F-fluorodeoxyglucose positron emission tomography (FDC-PET), with clinical outcome and changes in molecular pathology.
No measurements were reported for this outcome.
Assessed clinical efficacy of the combination regimen in this patient population per Progression-free survival (PFS). Progression-free survival (PFS) was the time from date of start of treatment to the date of first documented progression or death due to any cause. Per protocol (PP) population includes patients with no known overall lesion response during 4 months +/- 2 weeks, or who later had response of CR/PR/stable disease (SD). PP population excludes patients with no known response during 4 months + / -2 weeks and no subsequent CR/PR/SD.
| Percentage of participants | Phase ll - Stratum l (First-line Resistant/Refractory): RAD001 2.5mg/Day + Glivec 600mg/Day | Phase ll: Stratum ll (Post Second-line Therapy) |
|---|---|---|
| 4-Month Progression-free Survival (PFS) Rate - Phase II | 17.4 (5.0 to 38.8) | 37.1 (21.5 to 55.1) |
Assessed clinical efficacy of the combination regimen in this patient population per Progression-free survival (PFS). Progression-free survival (PFS) was the time from date of start of treatment to the date of first documented progression or death due to any cause. If a patient had not progressed or died, progression-free survival was censored at the time of last adequate tumor assessment. According to the study protocol no tumor assessments were performed after discontinuation of treatment with study drug. Therefore, for all patients who discontinued treatment without a documented progression but died thereafter, death was considered as PFS event only if it occurred within the regular safety follow-up of 28 days after discontinuation. Otherwise, the PFS time was censored at the last adequate tumor assessment.
| months | Phase ll - Stratum l (First-line Resistant/Refractory): RAD001 2.5mg/Day + Glivec 600mg/Day | Phase ll: Stratum ll (Post Second-line Therapy) |
|---|---|---|
| Progression-free Survival (PFS) - Phase II | 1.9 (1.8 to 3.7) | 3.5 (1.9 to 5.2) |
On treatment deaths were collected from FPFT up to 28 days after study drug discontinuation, for a maximum duration of 35.52 months (treatment duration ranged from 0.36 to to 35.52 months for the phase I part) and a maximum duration of 21.88 months (treatment duration of 0.16 to 21.88 months for the phase II part). Deaths post treatment survival follow up were collected after the on treatment period, up to 70 months.
| Participants | Phase l: RAD001 20mg/Week | Phase l: RAD001 2.5mg/Day + Glivec 600mg/Day | Phase l: RAD001 5mg/Day + Glivec 600mg/Day | Phase l: RAD001 2.5mg/Day + Glivec 800mg/Day | Phase ll - Stratum l (First-line Resistant/Refractory): RAD001 2.5mg/Day + Glivec 600mg/Day | Phase ll: Stratum ll (Post Second-line Therapy) |
|---|---|---|---|---|---|---|
| Total Deaths | 12 | 8 | 3 | 3 | 9 | 22 |
| Deaths on-treatment | 2 | 3 | 0 | 2 | 3 | 6 |
Collected over On-treatment deaths were collected from FPFT up to 28 days after study drug discontinuation, for a maximum duration of 35.52 months (treatment duration ranged from 0.36 to to 35.52 months for Phase I part) and a maximum duration of 21.88 months (treatment duration of 0.16 to 21.88 months for the Phase II part).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase I - RAD001 20mg/Week ++ Glivec 600mg/Day | — | 4/13 (30.8%) | 13/13 (100%) |
| Phase I: RAD001 2.5mg/Day + Glivec 600mg/Day | — | 7/13 (53.8%) | 12/13 (92.3%) |
| Phase I: RAD001 5mg/Day + Glivec 600mg/Day | — | 3/5 (60%) | 5/5 (100%) |
| Phase I: RAD001 2.5mg/Day + Glivec 800mg/Day | — | 7/11 (63.6%) | 11/11 (100%) |
| Phase ll - Stratum l (First-line Resistant/Refractory): RAD001 2.5mg/Day + Glivec 600mg/Day | — | 11/28 (39.3%) | 27/28 (96.4%) |
| Phase ll: Stratum ll (Post Second-line Therapy) | — | 25/47 (53.2%) | 47/47 (100%) |
| Event | Phase I - RAD001 20mg/Week ++ Glivec 600mg/Day | Phase I: RAD001 2.5mg/Day + Glivec 600mg/Day | Phase I: RAD001 5mg/Day + Glivec 600mg/Day | Phase I: RAD001 2.5mg/Day + Glivec 800mg/Day | Phase ll - Stratum l (First-line Resistant/Refractory): RAD001 2.5mg/Day + Glivec 600mg/Day | Phase ll: Stratum ll (Post Second-line Therapy) |
|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 2/13 | 3/13 | 2/5 | 0/11 | 1/28 | 8/47 |
| NauseaGastrointestinal disorders | 0/13 | 0/13 | 2/5 | 0/11 | 0/28 | 0/47 |
| VomitingGastrointestinal disorders | 1/13 | 0/13 | 2/5 | 0/11 | 1/28 | 2/47 |
| General physical health deteriorationGeneral disorders | 1/13 | 1/13 | 2/5 | 0/11 | 1/28 | 1/47 |
| Blood creatinine increasedInvestigations | 4/13 | 2/13 | 0/5 | 0/11 | 1/28 | 0/47 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/13 | 0/13 | 1/5 | 1/11 | 0/28 | 0/47 |
| DiarrhoeaGastrointestinal disorders | 1/13 | 0/13 | 1/5 | 1/11 | 1/28 | 0/47 |
| Gastritis haemorrhagicGastrointestinal disorders | 0/13 | 1/13 | 1/5 | 0/11 | 0/28 | 0/47 |
| MelaenaGastrointestinal disorders | 0/13 | 0/13 | 1/5 | 0/11 | 0/28 | 4/47 |
| PneumoniaInfections and infestations | 0/13 | 0/13 | 1/5 | 1/11 | 0/28 | 0/47 |
| Event | Phase I - RAD001 20mg/Week ++ Glivec 600mg/Day | Phase I: RAD001 2.5mg/Day + Glivec 600mg/Day | Phase I: RAD001 5mg/Day + Glivec 600mg/Day | Phase I: RAD001 2.5mg/Day + Glivec 800mg/Day | Phase ll - Stratum l (First-line Resistant/Refractory): RAD001 2.5mg/Day + Glivec 600mg/Day | Phase ll: Stratum ll (Post Second-line Therapy) |
|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 7/13 | 8/13 | 5/5 | 7/11 | 12/28 | 16/47 |
| FatigueGeneral disorders | 9/13 | 8/13 | 2/5 | 9/11 | 15/28 | 16/47 |
| Oedema peripheralGeneral disorders | 2/13 | 2/13 | 1/5 | 8/11 | 8/28 | 17/47 |
| DiarrhoeaGastrointestinal disorders | 8/13 | 5/13 | 2/5 | 7/11 | 12/28 | 17/47 |
| AnaemiaBlood and lymphatic system disorders | 6/13 | 7/13 | 3/5 | 4/11 | 12/28 | 22/47 |
| VomitingGastrointestinal disorders | 3/13 | 3/13 | 3/5 | 5/11 | 6/28 | 14/47 |
| PyrexiaGeneral disorders | 3/13 | 5/13 | 3/5 | 3/11 | 4/28 | 9/47 |
| Weight decreasedInvestigations | 4/13 | 3/13 | 3/5 | 2/11 | 6/28 | 8/47 |
| InsomniaPsychiatric disorders | 3/13 | 1/13 | 3/5 | 2/11 | 1/28 | 3/47 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/13 | 6/13 | 1/5 | 2/11 | 3/28 | 7/47 |
The Intent-to-treat population (ITT-population) consists of all patients who received at least one dose of RAD001 or Glivec/Gleevec in accordance to the study protocol.
| Age, Continuous(Years) | Phase l: RAD001 20mg/Week | Phase l: RAD001 2.5mg/Day + Glivec 600mg/Day | Phase l: RAD001 5mg/Day + Glivec 600mg/Day | Phase l: RAD001 2.5mg/Day + Glivec 800mg/Day | Phase ll - Stratum l (First-line Resistant/Refractory): RAD001 2.5mg/Day + Glivec 600mg/Day | Phase ll: Stratum ll (Post Second-line Therapy) | Total |
|---|---|---|---|---|---|---|---|
| Mean | — | — | — | — | 55.6 ± 13.16 | 59.3 ± 12.54 | 57.9 ± 12.81 |
| Age, Continuous(Years) | Phase l: RAD001 20mg/Week | Phase l: RAD001 2.5mg/Day + Glivec 600mg/Day | Phase l: RAD001 5mg/Day + Glivec 600mg/Day | Phase l: RAD001 2.5mg/Day + Glivec 800mg/Day | Phase ll - Stratum l (First-line Resistant/Refractory): RAD001 2.5mg/Day + Glivec 600mg/Day | Phase ll: Stratum ll (Post Second-line Therapy) | Total |
|---|---|---|---|---|---|---|---|
| Mean | 53.5 ± 5.25 | 52.2 ± 14.11 | 53.8 ± 11.95 | 61.9 ± 13.25 | — | — | 55.3 ± 11.80 |
| Sex: Female, Male(Participants) | Phase l: RAD001 20mg/Week | Phase l: RAD001 2.5mg/Day + Glivec 600mg/Day | Phase l: RAD001 5mg/Day + Glivec 600mg/Day | Phase l: RAD001 2.5mg/Day + Glivec 800mg/Day | Phase ll - Stratum l (First-line Resistant/Refractory): RAD001 2.5mg/Day + Glivec 600mg/Day | Phase ll: Stratum ll (Post Second-line Therapy) | Total |
|---|---|---|---|---|---|---|---|
| Female | 2 | 3 | 4 | 2 | 7 | 16 | 34 |
| Male | 11 | 10 | 1 | 9 | 21 | 31 | 83 |
| Race/Ethnicity, Customized(Participants) | Phase l: RAD001 20mg/Week | Phase l: RAD001 2.5mg/Day + Glivec 600mg/Day | Phase l: RAD001 5mg/Day + Glivec 600mg/Day | Phase l: RAD001 2.5mg/Day + Glivec 800mg/Day | Phase ll - Stratum l (First-line Resistant/Refractory): RAD001 2.5mg/Day + Glivec 600mg/Day | Phase ll: Stratum ll (Post Second-line Therapy) | Total |
|---|---|---|---|---|---|---|---|
| Caucasian | 13 | 12 | 5 | 11 | 27 | 47 | 115 |
| Black | 0 | 1 | 0 | 0 | 1 | 0 | 2 |
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the triasl in line with applicable laws and regulations. This trial data will be available according to the process described on www.clinicalstudydatarequest.com.
Data sharing details ↗ · www.clinicalstudydatarequest.com
No publications or documents are linked to this record.
Ran from Nov 2002 to primary completion in Sep 2008, 69 months.
Results were first posted in Jun 2021, 12 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Everolimus
Gastrointestinal Stromal Tumors →